reasonattlm

6 ms·

1.
by reasonattlm 2y ago
It is hard to cover everything related to longevity, given that there is a vast diversity of approaches, and a lot of work presently taking place. https://www.agingbiotech.info shows how much work goes into just making lists for
2.
by reasonattlm 3y ago
The 16S rRNA sequencing you are referring to is now quite cheap and efficient. [1] Viome is one of many companies offering this as a service. Viome isn't so good at giving you the underlying data, some of the others may be better; look
3.
by reasonattlm 3y ago
It is interesting that they achieved any positive results with prebiotics. The animal study evidence suggests that these are weak interventions compared to fecal microbiota transplant (FMT) from a young individual or flagellin immunization.
4.
by reasonattlm 5y ago
We should treat this study and the discussion of the relevance of the results as being highly speculative. Firstly, near all genetic variants that have been found to correlate with age in one study population fail to replicate in other stud
5.
by reasonattlm 6y ago
An entire article pondering regional differences in COVID-19 mortality and severity without saying anything about differing demographics of (a) aging and its comorbidities and (b) obesity and its comorbidities. SARS-CoV-2 is severe in old p
6.
by reasonattlm 6y ago
For a fairly inclusive list of longevity industry companies: https://agingbiotech.info/companies
7.
by reasonattlm 6y ago
If you can get into an incubator lab space that isn't in a major market like SF or Boston, where the rents are insane, one can expect to set up a reasonable wet lab for most uses given $200k in equipment and reagent costs and a couple
8.
by reasonattlm 6y ago
Several research groups and companies are working on in vivo applications of cellular reprogramming. Since its discovery, reprogramming has been used to produce induced pluripotent stem cells from any other type of cell. That process has be
9.
by reasonattlm 6y ago
This interesting open access paper recently published reports on the effects of hyperbaric oxygen treatment on telomere length and cellular senescence in immune cells taken from blood samples. I use the word "interesting" quite de
10.
by reasonattlm 6y ago
Some of the more noteworthy lessons I have learned to date as a result of running a longevity industry biotech startup, most of which likely apply to any biotech initiative, were incorporated into the "Notes on Starting a Biotech Compa
11.
by reasonattlm 6y ago
We don't need to end biological aging, just control it. Let aging run, producing molecular damage in tissues, and periodically repair and reverse that damage such that people don't become physically old. The SENS Research Foundati
12.
by reasonattlm 6y ago
Dasatinib + quercetin has been shown in a clinical trial to remove senescent cells in humans in much the same way it does in mice [1]. High dose fisetin (i.e. take a whole bottle of the stuff at one go, not just a couple of pills) works abo
13.
by reasonattlm 6y ago
Still as relevant 15 years later, as we still live in a world in which aging can be addressed via the construction of rejuvenation therapies, but most people are simply disinterested in the prospect, the science, and doing anything other th
14.
by reasonattlm 6y ago
No, no, no. This is just an argument for putting more effort into a failed strategy. The reason why we haven't made much progress towards extending healthy human life isn't because the disease state is complex, it is because the p
15.
by reasonattlm 6y ago
My company, Repair Biotechnologies, is working on regrowth of the atrophied thymus via FOXN1 upregulation. We're at the preclinical stage of getting the vector and formulation into shape, and the start of tests in influenza exposure mo
16.
by reasonattlm 7y ago
One of those hidden powers is the destruction of the aging brain. Senescence of glial cells appears to be quite important in the progression of neurodegeneration, as both a source of neuroinflammation and all of its woes, and a mechanism ca
17.
by reasonattlm 7y ago
Any bio* field can lead to working on treating aging; at undergraduate level you have tremendous flexibility as to which direction you take. For now build connections. Go to the conferences where industry meets science and meet people (Undo
18.
by reasonattlm 7y ago
A prediction: the generic, low-cost drug dasatinib, a senolytic that selectively destroys senescent cells and can pass the blood-brain barrier, will be the best Alzheimer's treatment of the next decade, starting just as soon as the May
19.
by reasonattlm 7y ago
I can't say as I like his take on the longevity industry. It is the take that will produce few meaningful advances, the "looking under the lamp because that's where the light is" way of approaching life. Just more margin
20.
by reasonattlm 7y ago
And yet the risk increase for dementia for people with periodontitis is not large at 6% in a recent sizable study. https://www.healthinaging.org/blog/periodontitis-may-raise-t...
21.
by reasonattlm 8y ago
Cancer research largely proceeds in the wrong direction, towards ever more personalization to mechanisms specific to one tiny fraction of cancer types, or tiny fraction of tumors in that cancer type. Then people are surprised at the low cos
22.
by reasonattlm 8y ago
From the SENS point of view [1] a number of the Hallmarks are downstream consequences of the causes of aging; e.g. epigenetic alterations are a reaction to molecular damage. Attempting to use those hallmarks as a place to intervene is doome
23.
by reasonattlm 8y ago
There are a bunch of other things that can't be fixed by delivering youthful stem cell populations into tissues, such as the presence of garbage molecules in long-lived somatic cell populations. Even youthful tissue can't break do
24.
by reasonattlm 8y ago
Testing per batch is needed when ordering direct from any manufacturer. In my experience there isn't any real difference in quality and order fulfillment between Chinese and non-Chinese manufacturers when it comes to extracts and resea
25.
by reasonattlm 8y ago
The only human study providing a compelling reason to try nicotinamide riboside is the one showing a drop in blood pressure in hypertensive adults [1]. But this was a very small group of patients. If it does that in most people (which it ma
26.
by reasonattlm 8y ago
The article falls a little far on the side of saying there is nothing wrong with a 60-something year old. There is a lot wrong with a 60-something year old. It might not yet rise to the level of constant debilitating pain and loss of basic
27.
by reasonattlm 8y ago
If a even a small fraction of the effort spent on trying and failing to cope with the realities of degenerative aging was spent on the current crop of plausible approaches to build medical biotechnologies that can reverse degenerative aging
28.
by reasonattlm 8y ago
Immunity is the standard problem for most vectors for gene therapy. Viral vectors have neutralizing antibodies, liposomes get eaten by macrophages, and so forth. Minimizing this issue to the degree needed for a therapy to work is the subjec
29.
by reasonattlm 8y ago
This is not all that important, save as a commentary on the fact that combinational treatments are not well explored in the research community. This is true throughout medicine, and not localized to aging research. Why not all that importan
30.
by reasonattlm 8y ago
If that study was isocaloric, then good for them for adding some human data to the existing animal data. I'll qualify my remark: most people who practice restricted eating hours in some way won't count calories or aggressively try

More ›